

# Martin Wermke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4714926/publications.pdf>

Version: 2024-02-01

41  
papers

2,432  
citations

516215

16  
h-index

360668

35  
g-index

42  
all docs

42  
docs citations

42  
times ranked

3125  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells. International Journal of Molecular Sciences, 2022, 23, 903.	1.8	7
2	Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. Blood Advances, 2022, 6, 3684-3696.	2.5	5
3	The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. European Journal of Cancer, 2022, 170, 106-118.	1.3	15
4	Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncology, 2022, 18, 2639-2649.	1.1	14
5	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal of Thoracic Oncology, 2021, 16, 289-298.	0.5	35
6	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550.	3.3	97
7	Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood, 2021, 137, 3145-3148.	0.6	70
8	Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. Journal of Thoracic Oncology, 2021, 16, 1952-1958.	0.5	32
9	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	1.4	27
10	503â€¦Clinical activity of ICT01, an anti-BTN3A-targeted, Î³Î²-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial. , 2021, 9, A535-A535.		0
11	Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study. Blood, 2021, 138, 2324-2324.	0.6	4
12	A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL). Blood, 2021, 138, 2436-2436.	0.6	5
13	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. Blood, 2021, 138, 3677-3677.	0.6	5
14	Targeted Therapy in BRAF p.K601Eâ€“Driven NSCLC: Case Report and Literature Review. JCO Precision Oncology, 2020, 4, 1163-1166.	1.5	8
15	Long-term in vivo imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenografts. Scientific Reports, 2020, 10, 13254.	1.6	20
16	Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on <i>FGFR</i> mRNA overexpression.. Journal of Clinical Oncology, 2020, 38, 527-527.	0.8	4
17	Comparative RNAi Screens in Isogenic Human Stem Cells Reveal SMARCA4 as a Differential Regulator. Stem Cell Reports, 2019, 12, 1084-1098.	2.3	10
18	Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth. Blood Advances, 2019, 3, 1695-1700.	2.5	19

#	ARTICLE	IF	CITATIONS
19	Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. <i>Lancet Haematology</i> , 2018, 5, e201-e210.	2.2	44
20	STK3 is a therapeutic target for a subset of acute myeloid leukemias. <i>Oncotarget</i> , 2018, 9, 25458-25473.	0.8	10
21	Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. <i>Oncoimmunology</i> , 2017, 6, e1342909.	2.1	22
22	Mammalian target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (<scp>MDS</scp>) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German <scp>MDS</scp> Study Group (D&MDS). <i>British Journal of Haematology</i> , 2016, 175, 917-924.	1.2	8
23	Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q. <i>Annals of Hematology</i> , 2016, 95, 1805-1810.	0.8	11
24	RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. <i>Blood</i> , 2015, 125, 3760-3768.	0.6	53
25	Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1248-1251.	2.0	64
26	Reconstitution of Interleukin-17-Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 357-365.	2.0	11
27	In Vivo Expansion of Co-Transplanted T Cells Impacts on Tumor Re-Initiating Activity of Human Acute Myeloid Leukemia in NSG Mice. <i>PLoS ONE</i> , 2013, 8, e60680.	1.1	22
28	Response and Long-Term Outcome After Treatment With Third-Party Mesenchymal Stromal Cells - Updated Results In 58 Patients With Steroid-Refractory Acute Graft-Versus Host Disease -. <i>Blood</i> , 2013, 122, 4612-4612.	0.6	1
29	Reconstitution of 6-Sulfo LacNAc Dendritic Cells After Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2012, 93, 1270-1275.	0.5	5
30	MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2012, 18, 6460-6468.	3.2	66
31	Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4167-4167.	0.6	0
32	Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4122-4122.	0.6	0
33	Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation â€“ a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients. <i>Blood</i> , 2011, 118, 489-489.	0.6	1
34	<sup>188</sup>Re antiâ€CD66 radioimmunotherapy combined with reducedâ€intensity conditioning and <i>inâ€vivo</i> T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2010, 148, 910-917.	1.2	21
35	Genetic Variations of Interleukin-23R (1143A>G) and BPI (A645G), but Not of NOD2, Are Associated with Acute Graft-versus-Host Disease after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1718-1727.	2.0	22
36	Comparing the Value of Serum Ferritin, Transfusion History and Magnetic Resonance Imaging for the Prediction of Iron Overload In MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 3493-3493.	0.6	0

#	ARTICLE	IF	CITATIONS
37	The HCT-Specific Comorbidity Index Fails to Predict Survival After Allogeneic HCT In High Risk AML Patients - A Single Center Experience. Blood, 2010, 116, 1326-1326.	0.6	0
38	BPI A645G SNP but Not NOD2 Genotype Predicts for Acute Lung Injury After Allogeneic Stem Cell Transplantation. Blood, 2010, 116, 2324-2324.	0.6	11
39	Appearance of Mature 6-Sulfo LacNAc+ Dendritic Cells In Early and Late Engraftment After Allogeneic Stem Cell Transplantation.. Blood, 2010, 116, 3720-3720.	0.6	0
40	Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes and Cancer, 2003, 37, 237-251.	1.5	133
41	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 2002, 99, 4326-4335.	0.6	1,550